# TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

> **NCT03829436** · PHASE1 · COMPLETED · sponsor: **Tempest Therapeutics** · enrollment: 38 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Metastatic Castration Resistant Prostate Cancer
- Renal Cell Carcinoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Squamous Cell Carcinoma of Head and Neck
- Triple-Negative Breast Cancer
- Urothelial Carcinoma
- Cholangiocarcinoma
- GastroEsophageal Cancer
- Pancreatic Cancer
- Sarcoma

## Interventions

- **DRUG:** Part 1 TPST-1120
- **DRUG:** Part 2 TPST-1120 + nivolumab
- **DRUG:** Part 3 TPST-1120
- **DRUG:** Part 4 TPST-1120 + nivolumab

## Key facts

- **NCT ID:** NCT03829436
- **Lead sponsor:** Tempest Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2022-09-07
- **Final completion:** 2022-09-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829436, "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03829436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*